Track topics on Twitter Track topics that are important to you
Tercica, Inc., based in Brisbane, Calif., is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the scientific and medical community to develop and commercialize therapeutics for growth and other endocrine disorders. In January 2006, less than four years after Tercica was founded, we commercially launched Increlex™ (mecasermin [rDNA origin] injection), or recombinant human Insulin-like Growth Factor-1 (rhIGF-1), in the United States. Increlex has received orphan drug exclusivity for its approved indication of the long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. In December 2005, we submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market Increlex in the European Union (EU) where the product has also been granted "orphan product" designation. We are currently conducting broad-scale Phase III clinical studies to evaluate the safety and efficacy of Increlex in children with Primary IGFD, which is a less extreme form of the product's approved severe Primary IGFD indication. Tercica licensed rights to develop, manufacture and commercialize Increlex from Genentech, Inc. Beyond Increlex, we are building a franchise of endocrinology products. In October 2006, we entered into a worldwide strategic collaboration agreement in endocrinology with Ipsen S.A. Under terms of the agreement, Ipsen granted Tercica exclusive rights to sell Somatuline® Autogel® (lanreotide) in the United States, subject to approval by the US Food and Drug Administration (FDA), and in Canada. Tercica granted Ipsen exclusive rights to sell Increlex in all regions of the world except the United States, Japan, Canada, Taiwan and certain countries of the Middle East and North Africa, subject to approval by relevant regulatory authorities. Also through this collaboration agreement, the companies granted each other certain rights to their respective endocrinology pipelines. Somatuline® Autogel® is an injectable sustained-release formulation containing lanreotide, a somatostatin analogue which inhibits the excess secretion of growth hormone and IGF-1. It is approved for the treatment of acromegaly and neuroendocrine tumors in over 50 countries worldwide. In July 2006, Health Canada approved Somatuline® Autogel® for the long-term treatment of patients with acromegaly due to pituitary tumors who have had inadequate response to or cannot be treated with surgery and/or radiotherapy and for the relief of symptoms associated with acromegaly. A New Drug Application was submitted to the FDA for the same indication on October 30, 2006.
2000 Sierra Point Parkway, Suite 400
United States of America
Phone: (650) 624-4900
Fax: (650) 624-4940
These highlights do not include all the information needed to use DYSPORT™ for Injection safely and effectively. See full prescribing information for DYSPORT™ for Injection. DYSPORT™ for Inject...
These highlights do not include all the information needed to use Somatuline Depot safely and effectively. See full prescribing information for Somatuline Depot. SOMATULINE® DEPOT (lanreotide) INJECT...
This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of p...
This is an extension study to Tercica study MS301 and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh I...
This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Tercica, Inc. In collaboration with participating health care practitioners, ...
Tercica, Inc., based in Brisbane, Calif., is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the scientific and medical community to dev...
We have published hundreds of Tercica news stories on BioPortfolio along with dozens of Tercica Clinical Trials and PubMed Articles about Tercica for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tercica Companies in our database. You can also find out about relevant Tercica Drugs and Medications on this site too.
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake. Diagnosis is based on clinical presentation...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...